Jair C. Soares
A5082192669- Bipolar Disorder and Treatment
- Functional Brain Connectivity Studies
- Tryptophan and brain disorders
- Schizophrenia research and treatment
- Electroconvulsive Therapy Studies
- Adolescent and Pediatric Healthcare
- Treatment of Major Depression
- Advanced Neuroimaging Techniques and Applications
- Genetics and Neurodevelopmental Disorders
- Electrolyte and hormonal disorders
- Neurological disorders and treatments
- Stress Responses and Cortisol
- Child and Adolescent Psychosocial and Emotional Development
- Advanced MRI Techniques and Applications
- Mental Health Research Topics
- Transcranial Magnetic Stimulation Studies
- Neuroscience and Neuropharmacology Research
- Autism Spectrum Disorder Research
- Attention Deficit Hyperactivity Disorder
- Obsessive-Compulsive Spectrum Disorders
- Genetic Syndromes and Imprinting
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Pharmacological Effects and Toxicity Studies
- Suicide and Self-Harm Studies
- Nerve injury and regeneration
The University of Texas Health Science Center at Houston
2016-2025
The University of Texas MD Anderson Cancer Center
2019-2024
Universitat de València
2023
Centro de Investigación Biomédica en Red de Salud Mental
2023
Harris Health System
2020-2023
Hochschule Fresenius
2022
Harris County Department of Education
2013-2021
The University of Texas Health Science Center at San Antonio
2003-2021
Baylor School
2010-2020
University of Houston
2019
Despite decades of research, the pathophysiology bipolar disorder (BD) is still not well understood. Structural brain differences have been associated with BD, but results from neuroimaging studies inconsistent. To address this, we performed largest study to date cortical gray matter thickness and surface area measures magnetic resonance imaging scans 6503 individuals including 1837 unrelated adults BD 2582 healthy controls for group while also examining effects commonly prescribed...
In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of proprietary, synthetic formulation psilocybin at 25 mg, 10 or 1 mg (control), along psychological support. The primary end point was the change from baseline week 3 in total score on Montgomery–Åsberg Depression Rating Scale (MADRS; range, 0 60, higher scores indicating more severe depression). Secondary points included response (≥50% decrease MADRS score),...
Considerable uncertainty exists about the defining brain changes associated with bipolar disorder (BD). Understanding and quantifying sources of can help generate novel clinical hypotheses etiology assist in development biomarkers for indexing disease progression prognosis. Here we were interested case-control differences intracranial volume (ICV) each eight subcortical measures: nucleus accumbens, amygdala, caudate, hippocampus, globus pallidus, putamen, thalamus, lateral ventricles. In a...
To investigate whether the cox-2 inhibitor celecoxib has antidepressant effects in bipolar disorder (BD) patients during depressive or mixed phases.We studied 28 DSM-IV BD who were experiencing a episode and on stable dose of mood stabilizer atypical antipsychotic medication. Subjects randomized to receive 6 weeks double-blind placebo (400 mg/day) treatment. Current medication remained at same doses trial.Intention-to-treat analysis showed that receiving had lower Hamilton Depression Rating...
Abstract Major depressive disorder (MDD) is associated with an increased risk of brain atrophy, aging-related diseases, and mortality. We examined potential advanced aging in adult MDD patients, whether this process clinical characteristics a large multicenter international dataset. performed mega-analysis by pooling measures derived from T1-weighted MRI scans 19 samples worldwide. Healthy was estimated predicting chronological age (18–75 years) 7 subcortical volumes, 34 cortical thickness...
COMP360 is a proprietary, synthetic formulation of psilocybin being developed for treatment-resistant depression (TRD), burdensome, life-threatening illness with high global impact. Here, we expand upon the previous report primary outcomes from phase 2 study in individuals TRD-the largest randomised controlled clinical trial psilocybin-to discuss findings exploratory efficacy endpoints.In this 2, double-blind trial, 233 participants TRD were to receive single dose 25 mg, 10 or 1 mg...